ProPublica and The New York Times look at the explosive spending growth related to an obscure medication for treating multiple sclerosis and a rare kidney disease — and how several top prescribers have links to drugmaker, Questcor Pharmaceuticals. The Wall Street Journal examines the impact of new drugs to treat hepatitis C.
Costly Specialty Drugs Drive Up Medicare Tab
No comments:
Post a Comment